Stay updated on Pembrolizumab Combo vs Alone in Stage III Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo vs Alone in Stage III Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab Combo vs Alone in Stage III Melanoma Clinical Trial page
- Check4 days agoChange DetectedAdded related topics entries for Melanoma and MedlinePlus Genetics to the study page's related topics section. This enhances navigational context by providing quick access to melanoma information and genetics resources.SummaryDifference0.1%

- Check12 days agoChange DetectedMelanoma was removed from the study’s condition listing. The related topics section, including MedlinePlus Genetics, was also deleted.SummaryDifference0.1%

- Check19 days agoChange DetectedMelanoma was added as a topic and related topics, including MedlinePlus Genetics, were linked to the page. The revision notice was updated to v3.6.3, replacing v3.6.2.SummaryDifference0.2%

- Check26 days agoChange DetectedThe page shows a new revision tag, v3.6.2, indicating an updated version. The previous revision tag, v3.6.0, has been removed along with Melanoma, the related topics header, and MedlinePlus Genetics from the page.SummaryDifference0.2%

- Check40 days agoChange DetectedThe page now indicates that recruitment has ended for this study, and adds user-help sections (How to Read a Study Record, Common Questions, How to Join a Study) to aid navigation. A formatting change updates the label from 'Intervention / Treatment' to 'Intervention/Treatment' and the revision tag advances from v3.5.5 to v3.6.0.SummaryDifference0.3%

- Check47 days agoChange DetectedRevision label updated from v3.5.4 to v3.5.5 on the page, indicating a new page/version release.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab Combo vs Alone in Stage III Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo vs Alone in Stage III Melanoma Clinical Trial page.